Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

6262 ARTÍCULOS , VIENDO DEL 2626 AL 2640

Neuroprotective potential of Epigenetic modulators, its regulation and therapeutic approaches for the management of Parkinson's disease

Kumari S, Gupta S, Sukhija R, Gurjar S, Dubey SK, Taliyan R.

Eur J Pharmacol. 2024 Dec 15;985:177123. doi: 10.1016/j.ejphar.2024.177123. Epub 2024 Nov 12.

A Global Perspective of GBA1-Related Parkinson's Disease: A Narrative Review

Koros C, Bougea A, Alefanti I, Simitsi AM, Papagiannakis N, Pachi I, Sfikas E, Antonelou R, Stefanis L.

Genes (Basel). 2024 Dec 16;15(12):1605. doi: 10.3390/genes15121605.

miR-221 and Parkinson's disease: A biomarker with therapeutic potential

Zamanian MY, Ivraghi MS, Gupta R, Prasad KDV, Alsaab HO, Hussien BM, Ahmed H, Ramadan MF, Golmohammadi M, Nikbakht N, Oz T, Kujawska M.

Eur J Neurosci. 2024 Jan;59(2):283-297. doi: 10.1111/ejn.16207. Epub 2023 Dec 3.

Microbiota, Tryptophan and Aryl Hydrocarbon Receptors as the Target Triad in Parkinson's Disease-A Narrative Review

Iwaniak P, Owe-Larsson M, Urbańska EM.

Int J Mol Sci. 2024 Mar 2;25(5):2915. doi: 10.3390/ijms25052915.

Exercise for People with Parkinson's Disease: Updates and Future Considerations

McGinley JL, Nakayama Y.

Phys Ther Res. 2024;27(2):67-75. doi: 10.1298/ptr.R0030. Epub 2024 Jul 19.

The epidemiology of Parkinson's disease

Ben-Shlomo Y, Darweesh S, Llibre-Guerra J, Marras C, San Luciano M, Tanner C.

Lancet. 2024 Jan 20;403(10423):283-292. doi: 10.1016/S0140-6736(23)01419-8.

Protective mechanism of Paeonol on central nervous system

Wu R, Liu Y, Zhang F, Dai S, Xue X, Peng C, Li Y, Li Y.

Phytother Res. 2024 Feb;38(2):470-488. doi: 10.1002/ptr.8049. Epub 2023 Oct 23.

ATP13A2 (PARK9) and basal ganglia function

Croucher KM, Fleming SM.

Front Neurol. 2024 Jan 5;14:1252400. doi: 10.3389/fneur.2023.1252400. eCollection 2023.

A review on the new age methodologies for early detection of Alzheimer's and Parkinson's disease

Ghosh N, Sinha K, Sil PC.

Basic Clin Pharmacol Toxicol. 2024 May;134(5):602-613. doi: 10.1111/bcpt.14003. Epub 2024 Mar 14.

Neuroinflammation and Dyskinesia: A Possible Causative Relationship?

Cardinale A, de Iure A, Picconi B.

Brain Sci. 2024 May 20;14(5):514. doi: 10.3390/brainsci14050514.

Cerebellar involvement in Parkinson's disease: Pathophysiology and neuroimaging

Qiu T, Liu M, Qiu X, Li T, Le W.

Chin Med J (Engl). 2024 Oct 20;137(20):2395-2403. doi: 10.1097/CM9.0000000000003248. Epub 2024 Sep 3.

[Commercial devices for monitoring symptoms in Parkinson's disease: benefits, limitations and trends]

Rodríguez-Martín D, Pérez-López C.

Rev Neurol. 2024 Oct 16;79(8):229-237. doi: 10.33588/rn.7908.2024253.

Delivery of Neuroregenerative Proteins to the Brain for Treatments of Neurodegenerative Brain Diseases

Ebert ET, Schwinghamer KM, Siahaan TJ.

Life (Basel). 2024 Nov 10;14(11):1456. doi: 10.3390/life14111456.

A review of the gastrointestinal, olfactory, and skin abnormalities in patients with Parkinson's disease

Almikhlafi MA.

Neurosciences (Riyadh). 2024 Jan;29(1):4-9. doi: 10.17712/nsj.2024.1.20230062.

Potential Roles of Nr4a3-Mediated Inflammation in Immunological and Neurological Diseases

He S, Jiang W, Jiang B, Yu C, Zhao G, Li Y, Qi L, Zhang J, Wang D.

Mol Neurobiol. 2024 Aug;61(8):5958-5973. doi: 10.1007/s12035-024-03945-8. Epub 2024 Jan 23.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias